Protocol Ledger

NCT06520345 · Phase III · RECRUITING

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Interventional Phase III clinical trial protocol NCT06520345 sponsored by Telix Pharmaceuticals (Innovations) Pty Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-26 Enrollment: 520 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06520345
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)520 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06520345
Protocol FieldVerified Registry Value
NCT IdentifierNCT06520345
Consolidated Lead SponsorTelix Pharmaceuticals (Innovations) Pty Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment520 participants (ESTIMATED)
Registered Start Date2024-07-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI